The use and value of procalcitonin in solid organ transplantation

Uriel Sandkovsky, Andre C Kalil, Diana F Florescu

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post-transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevated PCT levels after one wk of transplantation are correlated with infectious complications. PCT may be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serial PCT measurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post-transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.

Original languageEnglish (US)
Pages (from-to)689-696
Number of pages8
JournalClinical Transplantation
Volume29
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Calcitonin
Organ Transplantation
Transplantation
Biomarkers
Transplants
Infection
Immunosuppressive Agents
Bacterial Infections
Respiratory Tract Infections
Population
Therapeutics
Equipment and Supplies

Keywords

  • Allograft rejection
  • Heart transplant
  • Immunosuppressive therapy
  • Kidney transplant
  • Liver transplant
  • Procalcitonin
  • Solid organ transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

The use and value of procalcitonin in solid organ transplantation. / Sandkovsky, Uriel; Kalil, Andre C; Florescu, Diana F.

In: Clinical Transplantation, Vol. 29, No. 8, 01.08.2015, p. 689-696.

Research output: Contribution to journalReview article

@article{c7a1c77437e04d2dab6bddf5311e6808,
title = "The use and value of procalcitonin in solid organ transplantation",
abstract = "Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post-transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevated PCT levels after one wk of transplantation are correlated with infectious complications. PCT may be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serial PCT measurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post-transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.",
keywords = "Allograft rejection, Heart transplant, Immunosuppressive therapy, Kidney transplant, Liver transplant, Procalcitonin, Solid organ transplantation",
author = "Uriel Sandkovsky and Kalil, {Andre C} and Florescu, {Diana F}",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/ctr.12568",
language = "English (US)",
volume = "29",
pages = "689--696",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The use and value of procalcitonin in solid organ transplantation

AU - Sandkovsky, Uriel

AU - Kalil, Andre C

AU - Florescu, Diana F

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post-transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevated PCT levels after one wk of transplantation are correlated with infectious complications. PCT may be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serial PCT measurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post-transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.

AB - Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post-transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevated PCT levels after one wk of transplantation are correlated with infectious complications. PCT may be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serial PCT measurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post-transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.

KW - Allograft rejection

KW - Heart transplant

KW - Immunosuppressive therapy

KW - Kidney transplant

KW - Liver transplant

KW - Procalcitonin

KW - Solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=84937520684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937520684&partnerID=8YFLogxK

U2 - 10.1111/ctr.12568

DO - 10.1111/ctr.12568

M3 - Review article

C2 - 25996831

AN - SCOPUS:84937520684

VL - 29

SP - 689

EP - 696

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 8

ER -